Miromatrix Announces Two New Board Members
05 Janvier 2022 - 1:00PM
Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company
pioneering a novel technology for bioengineering fully
transplantable organs to help save and improve patients' lives,
today announced the expansion of the board and appointment of two
new board members: Lisa Wipperman Heine and William P. Burke.
"I am thrilled to welcome Lisa and Bill to the Miromatrix Board
as we continue developing bioengineered organs to address the
transplant shortage," said Jeff Ross, Ph.D., Miromatrix CEO. "Their
experience in growing innovative companies and leveraging strategic
partnerships make them exceptionally qualified to serve and further
advance the mission of Miromatrix."
Formerly, Lisa Wipperman Heine was the President and CEO of
PreCardia prior to its acquisition by Abiomed in 2021. In her more
than 25 year career, Ms. Heine has held a number of executive
management roles across both venture backed and public life science
and medical device companies, including medical, regulatory, and
clinical affairs. She also serves on the board of directors for
Surmodics (NASDAQ-SRDX) and Natus Medical (NASDAQ-NTUS).
"I am honored to be joining the Miromatrix board and look
forward to working with the entire team in addressing a major
public health issue and critical unmet patient need," said Ms.
Heine.
Bill Burke has served as CFO and Executive VP of Haemonetics
Corporation, a multinational company offering a comprehensive
portfolio of blood management devices and disposables, since 2016.
While there, he has led growth strategy development and, in 2021,
completed a $510M acquisition of Cardiva Medical. Mr. Burke held
the position of VP of Integration at Medtronic from 2014 to 2016.
Prior to that, he spent 20 years with Covidien, a global healthcare
products company.
"I am excited about the quality of leadership at Miromatrix, and
I look forward to the opportunity to work with the team to further
advance this revolutionary technology and save countless lives,"
said Mr. Burke.
About MiromatrixMiromatrix Medical Inc. is a
life sciences company pioneering a novel technology for
bioengineering fully transplantable human organs to help save and
improve patients' lives. The Company has developed a proprietary
perfusion technology platform for bioengineering organs that it
believes will efficiently scale to address the shortage of
available human organs. The Company's initial development focus is
on human livers and kidneys. For more information,
visit miromatrix.com.
Cautionary Statement Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements other than
statements of historical facts are forward looking statements,
including statements regarding our first ever transplant of a
bioengineered liver transplant into a large animal. In some cases,
you can identify forward-looking statements by terms such as "may,"
"will," "should," "expect," "plan," "anticipate," "could,"
"outlook," "guidance," "intend," "target," "project,"
"contemplate," "believe," "estimate," "predict," "potential" or
"continue" or the negative of these terms or other similar
expressions, although not all forward-looking statements contain
these words.
The forward-looking statements in this press release are only
predictions and are based largely on our current business plans,
expectations, and projections about future events and financial
trends that we believe may affect our business, financial
condition, and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of known and unknown risks, uncertainties and
assumptions, including, but not limited to, our history of
significant losses, which we expect to continue; our limited
history operating as a commercial company; our expectations with
respect to the regulatory pathway of our product candidates, our
ability to obtain regulatory approvals for such product candidates,
and the anticipated effect of delays in obtaining any such
regulatory approvals; our expectations with respect to preclinical
and clinical trial plans for our product candidates, the results of
such activities and the safety and efficacy of our product
candidates; our ability to commercialize our product candidates;
our ability to compete successfully with larger competitors in our
highly competitive industry; our ability to achieve and maintain
adequate levels of coverage or reimbursement for any future
products we may seek to commercialize; our ability to compete
successfully with larger competitors in our highly competitive
industry; our expectations regarding our manufacturing
capabilities; a pandemic, epidemic or outbreak of an infectious
disease in the U.S. or worldwide, including the outbreak of the
novel strain of coronavirus, COVID-19; product liability claims;
our ability to establish and maintain intellectual property
protection for our products, as well as our ability to operate our
business without infringing the intellectual property rights of
others; our ability to attract and retain senior management and key
scientific personnel; and other important factors that could cause
actual results, performance or achievements to differ materially
from those expected or projected. For information identifying
important factors that could cause actual results to differ
materially from those anticipated in the forward-looking
statements, please refer to the Risk Factors section of the
Company's Registration Statement on Form S-1 (File No. 333-256649),
as amended, filed with the U.S. Securities and Exchange Commission
and any additional risks presented in our Quarterly Reports on Form
10-Q and our Current Reports on Form 8-K.Except as expressly
required by applicable securities law, the Company disclaims any
intention or obligation to update or revise any forward-looking
statements whether as a result of new information, future events or
otherwise.
Investor ContactGreg Chodaczek347-620-7010
ir@miromatrix.com
Media Contact:press@miromatrix.com
Natus Medical (NASDAQ:NTUS)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Natus Medical (NASDAQ:NTUS)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024